A$2.45 0.1 2.1%
Last Trade - 17/01/20
| Market Cap | £854.4m |
| Enterprise Value | £847.1m |
| Revenue | £7.22m |
| Position in Universe | 205th / 1833 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | TTM | 2020E | 2021E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|---|
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2020
|
31st Dec 2021
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
PolyNovo Limited is a medical device company. The Company designs, develops and manufactures solutions for standalone and combination devices using its NovoSorb biodegradable polymer technology. The Company focuses on medical devices that are used in the treatment of burns, surgical wounds and negative pressure wound therapy (NPWT). It is involved in the development of NovoPore for use as a dressing in NPWT that involves a wound-contacting foam dressing, a sealing membrane, a suction pump, and a drainage tube from the dressing to a canister, and Biodegradable Temporising Matrix (BTM), a wound dressing focused on treatment of full-thickness wounds and burns where the dermal structure has been lost to trauma, or damaged requiring surgical removal, and requires a split-thickness skin graft for final closure. In addition, the Company is engaged in the development of breast sling prototypes for non-clinical and clinical trials, as well as new products for hernia and breast reconstructions.
| Last Annual | June 30th, 2019 |
| Last Interim | June 30th, 2019 |
| Incorporated | August 12, 1998 |
| Public Since | November 26, 1998 |
| No. of Shareholders: | 10,313 |
| No. of Employees: | 47 |
| Sector | Healthcare |
| Industry | Biotechnology & Medical Research |
| Index | S&P/ASX All Ordinaries , S&P/ASX 200 , S&P/ASX 300 , ASX Small Ordinaries , |
| Exchange | Australian Stock Exchange - SEATS |
| Shares in Issue | 661,088,044 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | U 2 320 Lorimer St, MELBOURNE, 3207, Australia |
| Web | http://polynovo.com.au/ |
| Phone | +61 3 86814050 |
| Auditors | Ernst & Young |
